Selank Amidate · Research brief

Semax vs Selank: Peptide Profiles, Effects, Duration

Real Peptides Research TeamEditorial

Updated September 21, 20268 min read

56 WORDS

Short answer

Semax and Selank get discussed like siblings. Chemically, they share exactly three of their seven amino acids, and nearly everything that distinguishes them sits in the four residues they don't have in common. Our team fields this question from research buyers most weeks: which sequence fits the model? The useful starting point isn't the marketing category.

Key takeaways

Semax and Selank are both synthetic heptapeptides sharing a Pro-Gly-Pro tail added to slow enzymatic degradation, but their active fragments come from unrelated sources: an ACTH fragment for Semax, the immune peptide tuftsin for Selank.
Reported semax vs selank peptide benefits diverge along that lineage, with Semax literature centred on neurotrophic, cognitive and ischemia endpoints and Selank literature on anxiolytic, stress and cytokine endpoints.
Both peptides show short plasma persistence reported in minutes, while reported effects in animal models are attributed to downstream gene expression changes that outlast the intact molecule.
Semax has an approximate molecular weight of 813.9 g/mol and Selank approximately 751.9 g/mol, a difference driven entirely by their non-shared residues.
Neither compound is FDA-approved; both hold Russian pharmacological registrations and are supplied strictly as research-use-only material.
Amidated variants of each sequence are chemically modified for greater reported stability, which is the main handling distinction between them and the base peptides.

Our team fields this question from research buyers most weeks: which sequence fits the model? The useful starting point isn't the marketing category. It's the parent molecule each peptide was carved from.

What is semax vs selank?

Semax vs selank compares two synthetic heptapeptides developed in Russia. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) derives from an ACTH fragment and appears in neurotrophic and cognitive research. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derives from tuftsin, an immune peptide, and appears in anxiolytic and immunomodulatory research. Both are research-use-only compounds with no FDA approval.

The oversimplification worth correcting is this: semax vs selank is not a stimulant-versus-sedative split. Published rodent work reports that both sequences influence brain-derived neurotrophic factor (BDNF), the protein supporting neuronal survival and synaptic plasticity, so the difference is one of pathway and emphasis rather than opposite directions. What follows covers sequence origins, reported effect profiles, pharmacokinetics and duration, reported tolerability, and how the purchasable formats differ in handling.

Two peptides, one shared tail

Both compounds are heptapeptides, meaning seven amino acids, and both terminate in the same Pro-Gly-Pro motif. That tail isn't decorative. It was appended by chemists at the Institute of Molecular Genetics of the Russian Academy of Sciences specifically to slow exopeptidase cleavage of each sequence's biologically active head.

The semax vs selank distinction begins with parentage. Semax takes its head from the ACTH(4-10) fragment of adrenocorticotropic hormone, keeping Met-Glu-His-Phe and dropping the residues associated with corticotropic activity. Its molecular weight is approximately 813.9 g/mol, and the literature describes it as retaining neurotropic behaviour without hormonal activity.

Selank takes its head from tuftsin, a four-residue immune peptide (Thr-Lys-Pro-Arg) released from the heavy chain of immunoglobulin G. Molecular weight is roughly 751.9 g/mol. That immune parentage is why selank vs semax peptide benefits diverge in the published record, with Selank studied against cytokine and Th1/Th2 balance endpoints that never appear in Semax work at all.

So is semax and selank the same? No. They share a synthetic stabilising tail and a country of origin. Their active fragments come from two unrelated biological systems, one endocrine, one immune. In our experience, labs that reason from the parent molecule rather than a bullet list of effects select the correct compound the first time.

Why the reported effects outlast the peptide

Here is where the semax vs selank comparison gets genuinely interesting, and where most forum summaries fall apart. Neither peptide has a long plasma half-life. Published pharmacokinetic work on both sequences reports rapid enzymatic degradation measured in minutes rather than hours, which is precisely why the Pro-Gly-Pro tail was engineered on in the first place.

Yet reported behavioural effects in animal models are described as persisting well beyond the point at which intact peptide is detectable. The mechanism proposed in the literature is downstream. Semax research reports changes in expression of BDNF and nerve growth factor (NGF) genes in the hippocampus, and transcriptional changes take hours to translate into protein, then persist independently of the original trigger. Selank research reports a comparably indirect route, including inhibition of enkephalin-degrading enzymes, which extends the life of endogenous enkephalins rather than the peptide acting as a receptor agonist itself.

Semax's own breakdown products complicate the picture further. Pro-Gly-Pro, the stabilising tail shared by both molecules, is itself reported to carry biological activity, so metabolite clearance and effect clearance are not running on the same clock.

That is the honest answer to how long Semax and Selank stay in the system. The molecules go quickly. The signature they leave behind does not.

Reported effects, reported tolerability, and the gaps

Semax appears in published work around cognition, attention, cerebral ischemia models and neuroprotection, and it holds a Russian pharmacological registration for cerebrovascular indications. Selank appears around anxiety-like behaviour, stress adaptation, sleep and immune modulation, and holds a Russian anxiolytic registration. Neither holds any FDA approval. That registration asymmetry is why questions like is semax or selank better rarely resolve cleanly: the two were developed toward different endpoints by different groups.

On side effects, semax vs selank data comes overwhelmingly from Russian clinical and preclinical groups, which describe generally mild tolerability, with local nasal irritation the most commonly noted complaint in intranasal study formats. We won't push past what the literature actually supports. Long-term safety data outside Russia is thin, there are no large Western phase 3 trials for either sequence, and absence of reported harm is not evidence of safety.

None of this is administration guidance. Both compounds are supplied for laboratory research only and are not for human or veterinary consumption, and any in vivo protocol should be reviewed with a licensed veterinarian and the relevant institutional committee before work begins. What we can speak to directly is material integrity: identity and purity should be confirmed against a batch certificate of analysis before a single data point is recorded.

Semax vs Selank: Side-by-Side Research Comparison

This table maps the parameters that actually change a study design rather than the ones that change a sales page. Intranasal delivery dominates the published work on both peptides, which is why searches for semax vs selank nasal spray are so common; in a laboratory setting the variable that matters is solution stability, not the bottle.

Research parameter	Semax	Selank	Bottom line for study design
Sequence and parent molecule	Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-10) fragment with corticotropic residues removed	Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from tuftsin, a tetrapeptide released from immunoglobulin G	Lineage predicts the literature: endocrine-derived for Semax, immune-derived for Selank
Primary reported mechanism	Reported upregulation of BDNF and NGF expression plus modulation of monoaminergic signalling	Reported GABAergic and serotonergic modulation plus inhibition of enkephalin-degrading enzymes	Both act indirectly; neither is described as a classical receptor agonist
Endpoints common in published work	Cognitive performance, attention, cerebral ischemia and neuroprotection models	Anxiety-like behaviour, stress adaptation, sleep parameters and cytokine balance	Select the compound whose endpoint literature matches your outcome measure
Plasma persistence and duration	Degradation reported in minutes; metabolite Pro-Gly-Pro reported to carry its own activity	Degradation reported in minutes; behavioural effects reported to persist longer in animal models	Sampling windows built around plasma levels will miss the reported effect window entirely
Formats and handling	Lyophilised powder and solution spray; amidate variant reported as more stable	Lyophilised powder and solution spray; amidate variant reported as more stable	Powder tolerates transit better; solutions demand cold-chain discipline at 2 to 8 degrees Celsius

What If: Research Planning Scenarios

What if a research model calls for both Semax and Selank?

Run them as separate arms before any combined arm. Co-administration confounds attribution because both sequences report influence on BDNF expression, so a combined result can't be assigned to either peptide without single-compound baselines. The shared Pro-Gly-Pro metabolite adds a second confounder, since both molecules generate it during degradation. Published head-to-head comparative work on the pair is limited, meaning most combination data circulating online is unpublished and uncontrolled.

What if a liquid spray peptide arrives warmer than expected?

Document the excursion, photograph the packaging and contact the supplier before opening anything. Peptides already in solution are far more vulnerable to thermal degradation than lyophilised powder, and no visual inspection at the bench will reveal whether an aqueous heptapeptide has partially hydrolysed. Solution formats are shipped cold and held refrigerated; lyophilised powder tolerates transit variation far better, which is one practical reason many labs default to it.

What if forum consensus contradicts the published literature?

Weight the literature. Semax vs selank reddit threads are genuinely useful for one thing, which is surfacing the questions researchers actually have, and unreliable for nearly everything else: no purity verification, no controls, no blinding, and heavy selection bias toward people who felt something and wanted to say so. Subjective timelines reported in those threads routinely conflict with published pharmacokinetics.

The unglamorous truth about peptide head-to-heads

Let's be direct about this: asking is semax and selank worth it is the wrong question until the endpoint is defined. Neither compound is a general-purpose upgrade over the other. Semax carries the deeper neurotrophic and ischemia literature, Selank carries the anxiolytic and immunological literature, and both bodies of work remain dominated by Russian research groups with limited independent Western replication. If a protocol can't state which measurable outcome it's testing, the semax vs selank choice is arbitrary, and arbitrary compound selection is how research budgets quietly evaporate.

Researchers comparing formats can read the full profiles on our Semax and Selank reference pages, weigh solution against powder with the Selank liquid spray, Semax liquid spray, Selank amidate and Semax amidate listings, or review adjacent peptides for immune system research across the full catalog.

Semax vs selank isn't a ranking problem, it's a parentage problem. One sequence traces back to a pituitary hormone fragment, the other to an antibody-derived immune peptide, and they happen to share a three-residue tail a Russian lab bolted on to keep both molecules intact long enough to study. Read them as siblings and you'll choose by impression. Read them as descendants of two unrelated biological systems and the right compound for a given model usually names itself before the protocol is finished.

References

Peer-reviewed sources on Selank indexed in PubMed, listed for research context. Real Peptides supplies Selank for laboratory research use only.

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine, 2022. PMID 36322304. doi:10.1007/s10517-022-05624-x
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Current reviews in clinical and experimental pharmacology, 2021. PMID 32621722. doi:10.2174/1574884715666200704152810
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. Bulletin of experimental biology and medicine, 2020. PMID 32651826. doi:10.1007/s10517-020-04868-9
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine, 2019. PMID 31625062. doi:10.1007/s10517-019-04588-9
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bulletin of experimental biology and medicine, 2019. PMID 31243679. doi:10.1007/s10517-019-04512-1
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters, 2018. PMID 30255741. doi:10.2174/0929866525666180925144642
Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bulletin of experimental biology and medicine, 2017. PMID 28853100. doi:10.1007/s10517-017-3817-8

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Semax vs selank is a comparison of two synthetic Russian heptapeptides. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) comes from an ACTH fragment and is studied for neurotrophic and cognitive endpoints. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) comes from the immune peptide tuftsin and is studied for anxiolytic and immune endpoints. Both are research-use-only.

Both are laboratory-synthesised seven-amino-acid peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Each was built by attaching a Pro-Gly-Pro tail to a shorter biologically active fragment to slow enzymatic breakdown. Semax derives from adrenocorticotropic hormone; Selank derives from tuftsin, an immunoglobulin-derived immune peptide.

Each is a heptapeptide, meaning a chain of seven amino acids joined by peptide bonds. Semax has an approximate molecular weight of 813.9 g/mol and Selank roughly 751.9 g/mol. They share only the terminal Pro-Gly-Pro motif; the remaining four residues of each sequence are completely different.

In published research, Semax appears in studies of cognition, attention, cerebral ischemia and neuroprotection, while Selank appears in studies of anxiety-like behaviour, stress adaptation, sleep and cytokine balance. Neither is FDA-approved for any use. Real Peptides supplies both strictly as research-grade material for laboratory investigation only.

Neither is better in general terms; they were developed toward different endpoints. Semax holds the deeper neurotrophic and ischemia literature, Selank the anxiolytic and immunomodulatory literature. The correct choice depends entirely on the outcome measure a study is testing, not on which peptide has more online discussion.

No. They share a synthetic Pro-Gly-Pro stabilising tail and a common country of origin, and nothing else structurally. Semax's active head comes from an endocrine hormone fragment, Selank's from an antibody-derived immune tetrapeptide. Those unrelated origins produce two largely non-overlapping bodies of published research.

That depends on whether the study has a defined, measurable endpoint that matches the existing literature. Both compounds have meaningful preclinical bodies of work, but replication outside Russian research groups remains limited. Labs without a clear outcome measure generally get little usable data from either sequence.

Published pharmacokinetic work reports rapid plasma degradation of both peptides, measured in minutes rather than hours. Reported effects in animal models persist considerably longer, which researchers attribute to downstream gene expression changes such as altered BDNF and NGF transcription rather than continued presence of the intact peptide.

Forum reports lack purity verification, controls, blinding and dose standardisation, and they skew heavily toward people who noticed an effect. Material sourced without a certificate of analysis may not even contain the stated sequence at the stated purity, which makes subjective timelines from those threads impossible to interpret.

Russian clinical and preclinical reports describe generally mild tolerability, with local nasal irritation most commonly noted in intranasal study formats. Long-term safety data outside Russia is limited and no large Western phase 3 trials exist for either peptide, so absence of reported harm should not be read as established safety.

Yes, mainly in stability. Peptides already in aqueous solution are more susceptible to hydrolysis and thermal degradation and require consistent refrigeration, while lyophilised powder tolerates shipping and storage variation far better. Visual inspection cannot detect partial degradation in a solution format, so cold-chain documentation matters more there.

Pricing varies with quantity, format and the documentation supplied, so compare per-milligram cost alongside analytical paperwork rather than headline price. Purity should be confirmed by a batch-specific certificate of analysis showing identity and purity testing for the exact lot shipped, not a generic sample certificate.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA